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Hepatic Complications
Tapani Ruutu and Enric Carreras
49.1  Introduction
The frequency and severity of TPH liver com-
plications have decreased sharply in the last 
decade, with some complications that have 
completely disappeared, such as, for example, 
Candida liver abscesses. The development of 
more effective strategies to preventing SOS/
VOD and GVHD has had a marked effect on its 
clinical presentation (see Chaps. 25 and 49). 
Finally, prophylaxis with antiviral and antifun-
gal drugs has greatly reduced the incidence of 
the most common liver infections (Hockenbery 
et al. 2016). The major liver complications after 
HSCT are:
Early after HSCT 
(<100 days)
Late after HSCT 
(months-years)
SOS/VOD
Acute GVHD  
(see Chap. 43)
Acute hepatitis
Pharmacological toxicity
Chronic GVHD  
(see Chap. 44)
Autoimmune hepatitis
Chronic viral hepatitis  
(see Chap. 38)
Cirrhosis and hepatocellular 
carcinoma
Iron overload  
(see Chap. 46)
Other less frequent
49.2  Sinusoidal Obstruction 
Syndrome
49.2.1  Definition
SOS, formerly called veno-occlusive disease of the 
liver (VOD), is the term used to designate the symp-
toms and signs that appear early after HSCT because 
of conditioning regimen-related hepatic toxicity. 
This syndrome is characterized by jaundice, fluid 
retention, and tender hepatomegaly appearing in the 
first 35–40 days after HSCT (Carreras 2015).
49.2.2  Pathogenesis
The hepatic metabolism of certain drugs (e.g., CY) 
by the cytochrome P450 enzymatic system pro-
duces several toxic metabolites (e.g., acrolein). 
These toxic metabolites are converted into stable 
(nontoxic) metabolites by the glutathione (GSH) 
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enzymatic system and then eliminated. When this 
process occurs in patients with a reduced GSH 
activity, caused by previous liver disease or by the 
action of agents such as BU, BCNU, or TBI, which 
consume GSH, toxic metabolites are not metabo-
lized. Toxic metabolites are predominantly located 
in area 3 of the hepatic acinus (around the centri-
lobular veins) because this area is rich in P450 and 
poor in glutathione. Consequently, damage to hepa-
tocytes and sinusoidal endothelium occurs predom-
inantly in this zone. Many other factors (see risk 
factors) can also contribute to endothelial injury.
The first events after endothelial injury caused 
by toxic metabolites are loss of fenestrae in sinusoi-
dal endothelial cells (SEC), formation of gaps 
within and between SEC, and rounding up or swell-
ing of SEC. Consequently, red blood cells penetrate 
into the space of Disse and dissect off the sinusoidal 
lining, which embolize downstream and block the 
sinusoids, reducing the hepatic venous outflow and 
producing post- sinusoidal hypertension. The 
changes observed in coagulation factors in these 
patients seem to be a consequence of the endothelial 
injury and probably play a secondary role in SOS 
pathogenesis, despite contributing to the sinusoidal 
occlusion (Carreras and Diaz-Ricart 2011).
49.2.3  Clinical Manifestations of SOS
Classical 
manifestations
Weight gaina/edema/ascites/
anasarca
Painful hepatomegaly/jaundice
Consumption of (not refractoriness 
to) transfused plateletsb
Manifestations of 
MOF
Pleural effusion/pulmonary 
infiltrates
Renal, cardiac, and pulmonary 
failure
Neurological symptoms 
(encephalopathy, coma)
aPositive fluid balance not explained by excessive 
hydration
bDifficult to demonstrate by expected thrombocytopenia
49.2.4  EBMT Diagnostic Criteria 
for Adults (Mohty et al. 2016)
Classical SOS 
(Baltimore criteria)a Late-onset SOSb
In the first 21 days 
after HSCT
Bilirubin ≥2 mg/dLc 
and ≥ 2 of the 
following
  –  Painful 
hepatomegaly
  –  Weight gain 
>5%
  –  Ascites
Classical SOS beyond day 21, 
OR
Histologically proven SOS
OR
≥2 of the classical criteria  
AND ultrasound (US) or 
hemodynamical evidence of 
SOS
aThese symptoms/signs should not be attributable to other 
causes
bMainly observed after conditioning including several 
alkylating agents (e.g., BU, MEL, or TT)
cObserved in almost 100% of adults but absent in up to 
30% of children
49.2.5  EBMT Diagnostic Criteria 
for Children  
(Corbacioglu et al. 2018)
No limitation for time of onset of SOSa
The presence of two or more of the followingb
  •  Unexplained consumptive and transfusion- 
refractory thrombocytopeniac
  •  Otherwise unexplained weight gain on 3 
consecutive days despite the use of diuretics or a 
weight gain >5% above baseline value
  •  Hepatomegaly (best if confirmed by imaging) 
above baseline valued
  •  Ascites (ideally confirmed by imaging) above 
baseline valued
  •  Rising bilirubin from a baseline value on 3 
consecutive days or ≥2 mg/dL within 72 h
aUp to 20% of children present late SOS
bWith the exclusion of other potential differential 
diagnoses
cWeight-adjusted platelet substitution/day to maintain 
institutional transfusion guidelines
dSuggested: imaging (US, CT, or MRI) immediately 
before HSCT to determine baseline value for both hepato-
megaly and ascites
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49.2.6  Incidence
Variable depending on the diagnostic criteria 
used, center experience, type of patients, and 
year of HSCT
Author (period analyzed) 
(study type)
Auto- 
HSCT Allo-HSCT
Coppell et al. 2010 
(1979–2007) (R)
8.7% 13%
Carreras et al. (1998) (P) 3.1% 8.9%
Corbacioglu et al. 2012 
(2006–2009) (P)a
6% 14%
Carreras et al. 2011 
(1997–2008) (R)b
– MAC, 8%/
RIC, 2%
R retrospective study, P prospective study
aOnly children and young adolescents
bOnly adults
49.2.7  Risk Factors for SOS
Patient-related risk factorsa,b
Age Younger < older
Sex Male < female
Karnofsky index 100–90 < lower than 90
Underlying 
disease
Nonmalignant < malignant < some 
specific diseasesc
Status of the 
disease
Remission < relapse
AST level before 
HSCT
Normal < increased
Bilirubin level 
before HSCT
Normal < increased
Prior liver 
radiation
No < yes
Liver status Normal < fibrosis, cirrhosis, tumor
Iron overload Absent < present
CMV serology Negative < positive
Prior treatment 
with
Gemtuzumab or inotuzumab 
ozogamicin
Concomitant drugs Progestogens, azoles
Genetic factors GSTM1-null genotype, MTHFR 
677CC/1298CC haplotype, etc.
Transplant-related factors
Type of HCT Syngeneic/autologous < allogeneic
Type of donor HLA-identical sibling < unrelated
Grade of 
compatibility
Match < minor mismatch < major 
mismatch
T-cell in the graft T-cell depleted < non-T-cell 
depleted
Type of 
conditioning
NMA < RIC < TRC < MAC
Busulfan IV < oral targeted < oral
CY-BU < BU-CY
TBI Fractionated < single dose
Low-dose rate < high-dose rate
Less than 12 Gy < more than 12 Gy
Time between CY to TBI 
36 h < CY to TBI 12 h
Fludarabine Not included < included
GvHD prophylaxis CNI (TAC < CSA) 
< CNI + sirolimus
HSCT number First < second HSCT
Bold characters indicate the most relevant factors
aMany factors have been associated with an increased risk 
of SOS, with those in bold letters seem the most relevant
bRemember that the presence of several risk factors in a 
patient has an additive effect
cDue to unknown causes, some malignant or nonmalignant 
diseases, osteopetrosis, adrenoleukodystrophy, thalassemia, 
hemophagocytic lymphohistiocytosis, or neuroblastoma 
are associated with a higher incidence of SOS
49.2.8  How to Confirm 
the Diagnosis?
SOS is a syndrome and must be diagnosed clinically, 
but several tools can help us
Transjugular 
hemodynamic 
study
Permits a safe measurement of the 
hepatic venous pressure gradient 
(HVPG), which evaluates the presence 
of intrahepatic post- sinusoidal 
hypertension. A HVPG >10 mmHg is 
highly specific (>90%) and moderately 
sensitive (60%) for SOS
Transvenous 
liver biopsies
Transvenous biopsies may be obtained 
during hemodynamic studies, but 
false-negative results could be 
obtained due to the patchy nature of 
SOS. However, biopsies carry a risk of 
hemorrhagic complications (e.g., into 
the peritoneum and biliary tract). 
Consequently, they are only indicated 
when a crucial differential diagnosis is 
required (e.g., SOS versus GVHD?)
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Imaging 
techniques
They may be helpful to confirm 
hepatomegaly and/or ascites (relevant 
in overweight patients) and for the 
differential diagnosis. Baseline and 
serial US may be useful for early 
detection of SOS
The US abnormalities observed in 
SOS (hepatomegaly, splenomegaly, 
gallbladder wall thickening, ascites) 
are not specific. Decrease in velocity 
or reversal of the portal venous flow is 
considered more specific for SOS but 
usually occurs late in the disease 
(reviewed in Dignan et al. 2013)
Composite 
biomarkers
Recently some composite markers 
have shown a prognostic value at day 
0 (L-Ficolin, HA, VCAM-1) and at 
diagnosis (ST2, ANG2, L-Ficolin, HA, 
VCAM-1) (Akil et al. 2015)
HA hyaluronic acid, VCAM-1 vascular cell adhesion mol-
ecule- 1, ST2 suppressor of tumorigenicity-2, ANG2 
angiopoietin-2
49.2.9  EBMT Criteria for Severity Grading
Classically the severity of SOS was stablished, 
prospectively, based in a mathematical model or, 
retrospectively, based on its evolution (resolution 
or not at day +100). Later, SOS may be classified 
as severe with the development of multiorgan 
failure MOF. Several systems have been proposed 
for early prognostication of SOS using scales, 
including the following elaborated by the EBMT 
(Mohty et al. 2016).
Mild Moderate Severe Very 
severe
Time since first 
symptoms
>7 days 5–7 days ≤4 days Any time
Bilirubin mg/dL ≥2 to <3 ≥3 to <5 ≥5 to <8 ≥8
Bilirubin 
kinetics
Doubling 
in 48 h
Transaminases 
(× N)
≤2 >2 to ≤5 >5 to ≤8 >8
Weight gain (%) <5 ≥5 to <10a ≥5 to <10a ≥10
Renal function 
(× baseline at 
HSCT)
<1.2 ≥1.2 to 
<1.5
≥1.5 to <2 ≥2 or 
other data 
of MOF
This severity grading must be applied once SOS/VOD has 
been diagnosed applying the criteria mentioned in 49.2.4
Patients belong to the category that fulfills ≥2 criteria. If 
patients fulfill ≥2 criteria in two different categories, they 
should be classified in the most severe category
In the presence of two or more risk factors for SOS, patients 
should be in the upper grade
N normal values
aWeight gain ≥5% and <10% is considered as a severe 
SOS. However, if the patient does not fulfill other criteria 
for severe SOS, it is therefore considered a moderate SOS
49.2.10  Prophylaxis (Dignan et al. 
2013; Carreras 2015)
Non-pharmacological measures
Avoid modifiable risk factors: Treat Iron overload 
(chelation); treat viral hepatitis; delay HSCT if active 
hepatitis; reduce intensity of conditioning; use 
CY + BU instead of BU + cy; try to avoid CNI  
(if not possible use TAC instead CSA) for GVHD 
prophylaxis; avoid hepatotoxic drugs (progestogens)
Pharmacological Drug (degree of 
recommendation)
Not recommended Sodium heparin (2B), 
low-molecular-weight 
heparin (2B), 
antithrombin III (2B), 
prostaglandin-1 (1B), 
pentoxifylline (1A)
Suggested Ursodeoxycholic acid 
(2C)a
Defibrotide: In 
high-risk adult patients 
(2B)
Recommended Defibrotide: In 
high-risk children (1A) 
[25 mg/kg/d]
aIn two randomized trials, UDCA reduce the incidence of 
SOS but in other two this effect was not observed. However, 
in all them, patients with UDCA have a lower TRM
49.2.11  Treatment (Degree 
of Recommendation) 
(Dignan et al. 2013;  
Carreras 2015)
Methylprednisolone (2C): Used by some 
authors. Recommended doses not defined 
(and range from high to low) and results dif-
ficult to analyze. Main risk: to delay treatment 
with defibrotide, the only agent with proved 
effectiveness.
Defibrotide (1B): Despite the absence of ran-
domized studies, it is the only agent approved by 
FDA and EMA to treat severe SOS (>80% mor-
tality). In these patients: 50% of complete remis-
sion and > 50% SRV at day +100. Early treatment 
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strongly recommended. Dose: 6.25 mg/kg q6h in 
2 h during ≥21 days, depending on the response.
49.3  Hepatitis After HSCT
Despite the reduction in the incidence of liver 
complications after HSCT, there remain multiple 
hepatic causes of elevations of serum alanine 
aminotransferase (ALT). In addition to the acute 
viral hepatitis, other noninfectious causes must 
be considered:
VZV, CMV, 
EBV, HHV-6
Infrequent (see Chap. 38)
HBV, HCV, 
HEV
(see Chap. 38)
Drug-induced 
hepatitis
Very frequent. Wide range of severity 
(see Sect. 49.3.1)
Hepatic GvHD Exceptional. AST/ALT >2000 U/L 
usually observed in patients without 
or with minimal IS (or receiving DLI) 
(see Chaps. 43 and 44)
Autoimmune 
hepatitis
True autoimmune hepatitis or 
GVHD? Often difficult to 
differentiate (see Sect. 49.3.2)
Other causes Severe SOS (see Sect. 49.2), hypoxic 
liver injury (septic or cardiac shock or 
respiratory failure), acute biliary 
obstruction
49.3.1  Drug Induced Hepatitis
Druga,b Comments
Thiazole antifungalsc Cholestaticd or 
hepatocellular hepatitise, 
liver failure
Echinocandins Cholestatic hepatitis or 
mild-moderate 
hepatocellular hepatitis
Fluoroquinolones Hepatocellular hepatitis
Liposomal AmB Mild-moderate elevation 
of alkaline phosphatase
TMP/SMX Hepatocellular hepatitis
CSA, tacrolimus Cholestasis. Dose- 
dependent effect
Rapamycin Hepatocellular damage, 
increased risk of SOSf
Anticonvulsants Hepatitis, hepatocellular 
or cholestatic
Druga,b Comments
NSAIDs Hepatitis, hepatocellular 
or cholestatic
Acetaminophen Hepatocellular hepatitis. 
Dose-dependent effect
Antidepressants Hepatocellular hepatitis. 
Unrelated to drug dosage
Ranitidine Cholestatic hepatitis, 
eosinophilic infiltration
Amoxicillin-clavulanic 
acid
Cholestatic and/or 
hepatocellular hepatitis
Antihypertensive 
drugs + lipid-lowering 
agents + oral 
hypoglycemics
Drugs usually associated 
in patients with metabolic 
syndrome (see Chap. 55)
AMB amphotericin B, TMP/SMX trimethoprim- 
sulfamethoxazole, NSAID nonsteroidal anti-inflammatory 
drug
aOther than cytostatic drugs
bOnline resources for the consultation of toxicities and 
interactions: https://livertox.nlm.nih.gov
cVoriconazole, posaconazole
dLiver damage with predominant elevation of bilirubin 
and alkaline phosphatase
eHepatic damage with predominant elevation of 
transaminases
fEspecially if associated to CNI
49.3.2  Autoimmune Hepatitis (AIH)
The main problem with this hepatitis is how to 
differentiate them from a hepatic GVHD, since 
pathogenesis, clinical manifestations, and bio-
logical changes are practically identical (Dalekos 
et al. 2002).
Autoimmune 
hepatitis Hepatic GVHD
Jaundice Usually mild Various degrees
Other 
symptoms
Fatigue, malaise, 
many times 
asymptomatic
Hepatic tenderness, 
dark urine, acholic 
stools, anorexia, 
usually GVHD in 
other organs
Pathology Inflammatory 
infiltrate in portal 
area, often 
penetrating lobes
Inflammatory 
infiltrate, loss of small 
bile duct, 
degeneration of bile 
ductular epithelium, 
cholestasis
Cirrhosis May be present Rare
>AST Moderate to 
severe
Less striking
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Autoimmune 
hepatitis Hepatic GVHD
>GGT Marked Usually normal o 
decreased
Auto-Ab Type AIH-2 
(ALKM, ALC-1)
Often found (AIH-1) 
(ANA, ANCA, etc.)
Response 
to steroids
Excellent Depends on severity
In bold letter main differential data
49.4  Cirrhosis and Heparocellular 
Carcinoma
Cirrhosisa – In HSCT with HBV: exceptional
–  In HSCT with HCV: 11% at 15 years; 
20% at 20 years (Peffault de Latour 
et al. 2004)b
–  In HSCT with HEV: frequency not 
known but rapidly progressive cases 
have been reported (see Chap. 38)
–  Poorly compensated cirrhosis is a 
contraindication for HSCT because of the 
prohibitive risk of developing SOS after 
MAC. Even compensated cirrhosis has a 
high likelihood of hepatic decompensation 
after NMA (Hogan et al. 2004)
Carcinoma In patients with chronic HCV: 5% at 
20 years of new cases per year (Peffault de 
Latour et al. 2004). These patients should 
undergo surveillance with six monthly 
liver ultrasound scans according to 
international guidelines
aThese data correspond to the times when new antiviral 
agents were not available. No updated data are available
bThe cumulative incidence of severe liver complications 
in HSCT infected with the HCV was 11.7% at 20 years in 
multicenter cohort (Ljungman et al. 2012)
49.5  Other Less Frequent Hepatic 
Complications
49.5.1  Nodular Regenerative 
Hyperplasia
After HSCT, occasionally observed in patients 
with a previous SOS/VOD.
Pathogenesis: Probable consequence of changes 
in liver blood flow with atrophy of zone 3 of the 
acinus and hypertrophy of zone 1 (without 
fibrosis).
Clinical Manifestations: Silent evolution (occa-
sionally increase of AP) until the appearance of 
portal hypertension (ascites, splenomegaly, 
thrombocytopenia).
Diagnosis: Investigated by imaging (primarily 
MRI). Liver biopsy can rule out carcinoma and 
cirrhosis; need for a needle biopsy (not transjug-
ular or fine-needle biopsy).
49.5.2  Focal Nodular Hyperplasia
In one series (Sudour et al. 2009) of HSCT survi-
vors undergoing liver MRI, these lesions were 
observed in 12%.
Pathogenesis: The likely cause is sinusoidal 
injury caused by myeloablative conditioning 
regimens.
Clinical Manifestations: Asymptomatic.
Diagnosis: By MRI, lesions have characteristic 
central scars that differentiate them from 
hepatocellular carcinoma and fungal lesions.
49.5.3  Idiopathic Hyperammonemia
Very rare. Observed after conditioning (Frere 
et al. 2000)
Diagnosis: Severe hyperammonemia (>200 
μmol/L) with minimal alteration of other LFTs.
Clinical Manifestations: Lethargy, motor dysco-
ordination, and alkalosis.
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